Minaris and Asimov Partner to Advance AAV Manufacturing with OXGENE Technology
Why now
Thesis: Private manufacturing tie-up, niche impact
Catalyst to watch: Manufacturing yield data
Main risk: Private parties, unquantified benefit
Why it matters
Manufacturing partnership targets gene-therapy yields; private CDMO deal, no listed impact.
Details
Asimov to integrate Minaris' OXGENE technology into its AAV Edge producer cell lines to unlock higher manufacturing titers and improved product quality. PHILADELPHIA and BOSTON, Sept. 24, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) CDMO and multimodal biosafety...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-24 12:00 UTC